NKGN NKGen Biotech Inc revenue, earnings and financials
For the quarter ended March 31, 2025, NKGen Biotech Inc reported revenue of n/a, net income of $15.4M and diluted EPS of −$0.04; for the fiscal year ended December 2024 revenue was n/a.
NKGN annual revenue and earnings
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$27.0M, net income −$44.3M (margin n/a), EPS −$1.54
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$29.7M, net income −$83.0M (margin n/a), EPS −$5.38
- Fiscal year ended Dec 2022: revenue $77.0K, gross profit n/a, operating income −$24.3M, net income −$26.8M (margin -34745.5%), EPS −$4.21
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$2.51M, net income −$991K (margin n/a), EPS −$0.07
NKGN quarterly revenue and earnings
- Quarter ended Mar 31, 2025: revenue n/a, net income $15.4M, EPS −$0.04
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$29.4M, EPS −$0.77
- Quarter ended Sep 30, 2024: revenue n/a, net income $6.60M, EPS $0.15
- Quarter ended Jun 30, 2024: revenue n/a, net income −$16.1M, EPS −$0.67
- Quarter ended Mar 31, 2024: revenue n/a, net income −$5.38M, EPS −$0.25
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$33.6M, EPS −$1.68
- Quarter ended Sep 30, 2023: revenue $0 (down 100.0% year over year), net income −$33.2M, EPS −$2.48
- Quarter ended Jun 30, 2023: revenue n/a, net income −$7.85M, EPS −$0.59
- Quarter ended Mar 31, 2023: revenue n/a, net income −$8.32M, EPS −$0.63
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$23.0M, EPS −$3.24
- Quarter ended Sep 30, 2022: revenue $3.00K, net income −$6.69M, EPS −$1.10
- Quarter ended Jun 30, 2022: revenue n/a, net income $956K, EPS $0.04
- Quarter ended Mar 31, 2022: revenue n/a, net income $2.00M, EPS $0.09
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$1.34M, EPS n/a
- Quarter ended Sep 30, 2021: revenue n/a, net income $4.69M, EPS $0.22
- Quarter ended Jun 30, 2021: revenue n/a, net income −$4.31M, EPS n/a
- Quarter ended Mar 31, 2021: revenue n/a, net income −$35.7K, EPS −$0.01
NKGN cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$20.9M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$21.9M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$22.6M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$1.52M, share buybacks n/a
NKGN balance sheet
- Mar 31, 2025: cash $6.00K, total assets $15.8M, total liabilities $66.2M, shareholders' equity −$50.3M
- Dec 31, 2024: cash $106K, total assets $16.2M, total liabilities $86.1M, shareholders' equity −$69.9M
- Sep 30, 2024: cash $8.00K, total assets $15.0M, total liabilities $62.0M, shareholders' equity −$47.1M
- Jun 30, 2024: cash $79.0K, total assets $15.6M, total liabilities $85.4M, shareholders' equity −$69.7M
- Mar 31, 2024: cash $34.0K, total assets $16.3M, total liabilities $71.4M, shareholders' equity −$55.1M
- Dec 31, 2023: cash $26.0K, total assets $16.5M, total liabilities $75.2M, shareholders' equity −$58.7M
- Sep 30, 2023: cash $8.79M, total assets $25.2M, total liabilities $65.8M, shareholders' equity −$40.6M
- Jun 30, 2023: cash $41.5K, total assets $63.6M, total liabilities $9.35M, shareholders' equity −$12.4M
Is NKGN profitable?
No. NKGen Biotech Inc lost $23.6M over the last four quarters.
What is NKGN's EPS?
Diluted earnings per share over the last four quarters were −$1.33; −$0.04 in the latest quarter.